| Verified against primary record | |
| Regulator position | No proven clinical benefit from young donor plasma infusion for ageing or memory loss[1] |
|---|---|
| Restated five years later | Not approved for any such use, and no evidence of effectiveness known to the regulator[2] |
| Registration is not approval | Being registered, or listing a study on a trials register, does not constitute approval[2] |
| Records read | Two regulator notifications and the WHO ageing initiative, 30 September 2026 |
| Independently reported | |
| Accreditation | No independent accreditor of this sector was identified |
| Bands apply only to the rows beneath them. No market size figure appears, because every such figure traces to commercial research with paywalled methodology. | |
Longevity tourism is travel to clinics offering interventions intended to slow, arrest or reverse biological ageing. It is a recent commercial sector, marketed to people who are well rather than ill, and its defining characteristic from a reference point of view is that almost nothing in it has been assessed by an external body.
What a regulator has actually said
The clearest regulatory statement concerns one of the sector’s flagship offerings. In February 2019 the United States Food and Drug Administration issued a notification about young donor plasma infusions marketed for profit, noting that they were being sold for a variety of conditions ranging from normal ageing to memory loss and for conditions including dementia, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, heart disease and post-traumatic stress disorder. It stated that there is no proven clinical benefit of the infusion of plasma from young donors in the prevention or treatment of such conditions, that plasma is not approved to treat conditions such as normal ageing or memory loss, and that there have not been any well-controlled studies showing clinical benefit for these uses. It identified infectious risk, allergic reactions, transfusion-related acute lung injury and cardiovascular complications as risks.[1]
In December 2024 it returned to the subject, stating that it has not approved young plasma for any such uses and is not aware of evidence demonstrating effectiveness for them, and noting that establishments have continued to market it.[2]
The most useful part of that update is a clarification aimed squarely at the sector’s standard response. It states explicitly that being registered with the regulator, or listing a study on a clinical trials register, does not constitute approval.[2] Both claims are common in the marketing of these clinics, and both are addressed directly.
A similar position applies to the cell-based interventions this sector also sells. The same regulator states that the only approved stem cell products are blood-forming stem cells derived from umbilical cord blood and that there are no approved exosome products, warning that patients may be misled by information about products that are illegally marketed and have not been shown to be safe or effective.[3] That alert is directed at orthopaedic, neurological, cardiovascular and pulmonary marketing claims rather than at anti-ageing claims specifically.
The legitimate counterpart
Healthy ageing as a field of public health exists and looks nothing like the commercial sector. The United Nations Decade of Healthy Ageing, running from 2021 to 2030, is organised around four action areas: combatting ageism, creating age-friendly environments, delivering integrated care, and providing long-term care.[4] None of these is a purchasable intervention, and none is what longevity clinics sell.
What does not exist
No independent accreditor of longevity clinics was identified for this entry. A search returned only commercial certification products sold to practitioners by training companies and trade associations, which are a different thing: a practitioner credential sold by an interested party is not a facility accreditation by an independent body. This is a negative search result rather than an authoritative statement that no accreditor exists, but it is consistent with what the regulatory record shows.
No market size figure appears in this entry either. Every circulating figure for the longevity clinic market originates with commercial market research firms whose methodology sits behind a paywall and cannot be examined.
See also
- Stem cell tourism, which sells overlapping interventions
- Health screening abroad, the other product aimed at people who are well
- Wellness tourism, the category this sector positions itself against
- Medical travel for unavailable treatments, for the regulatory framework on unapproved products
References
- United States Food and Drug Administration. Important Information about Young Donor Plasma Infusions for Profit. 19 February 2019. Verified against primary record: regulator safety notification opened and read. Retrieved 30 September 2026.
- United States Food and Drug Administration. Update to Important Information about Young Donor Plasma Infusions Offered for Profit. 6 December 2024. Verified against primary record: regulator update opened and read. Retrieved 30 September 2026.
- United States Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Published 22 July 2020, updated 9 April 2024. Verified against primary record: regulator alert opened and read. Retrieved 30 September 2026.
- World Health Organization. UN Decade of Healthy Ageing 2021 to 2030. Verified against primary record: institutional initiative page opened and read. Retrieved 30 September 2026.
Sourcing note: the two regulator notifications, the consumer alert and the WHO initiative page were opened and read on 30 September 2026. The statement that no accreditor of this sector exists is reported as a negative search result rather than as an authoritative absence, because no regulator or standards body has stated it. The regenerative medicine alert is noted as addressing marketing claims other than anti-ageing ones, so that it is not over-read. No market size figure appears, and the reason is stated.